Russian Federation to Complete Registration of Second COVID-19 Vaccine by 15 October

Russian Federation to Complete Registration of Second COVID-19 Vaccine by 15 October

It said it had received commitments for $1.4 billion towards vaccine research and development, but a further $700m-$800m was urgently needed.

According to the government official, most laboratories and countries developing the vaccine claim that the first doses are expected to be available in the first quarter of next year, as had been reported to the population.

The approach is different from many places in the world.

The COVAX Facility is part of COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, which is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi and the WHO, in partnership with developed and developing country vaccine manufacturers, UNICEF, the World Bank, civil society organizations and others. This shields the developers because widespread inoculation against the disease is considered a benefit to society.

The Russian Direct Investment Fund will supply 100 million doses to Dr Reddy's Laboratories.

A volunteer is injected with AstraZeneca's coronavirus vaccine as part of the trial. The delays have persisted even as the virus infects more than 5,000 people a day in Russian Federation.

Beijing has focused on cutting one-on-one deals for vaccine doses.

Codagenix is a clinical-stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors.

The final trial of Russia's pioneering Sputnik V vaccine, officially registered on August 11, is in full swing.

"We are confident in the long-term consequences", Dmitriev said. "We urge those countries who have not yet signed up to do so". However, he did not say how many doses were sent and by when they would be available.

Dr. Tambe said that it is likely that trials might begin from Monday itself. Some vaccines might require cold storage, meaning they won't suit populations in countries where cold store distribution is limited.

Coronavirus (COVID-19) vaccine: almost nine months into the novel coronavirus pandemic, there is a global race to develop a vaccine to control the transmission of the disease.

Late-stage trials, known as Phase III, are now ongoing in Russian Federation, with at least 40,000 volunteers taking part.

It can be seen that the Novavax vaccine candidate is now undergoing phase-2 clinical trials in South Africa.

Another 34 are tipped to sign up soon although, notably, both the United States and China are absent from the list.

Dmitriev said he was not concerned about the risk of compensation claims against RDIF.

"We'll finally get to know as much as possible in the Phase 3 trial - its final efficacy and whether it has been proven [as effective against the coronavirus]". EMA must authorise vaccines before they can be used in the EU. About $15 billion is needed immediately to maintain momentum and stay on track, he said.

However, while MEPs welcomed the collaborative efforts made so far to accelerate the development and subsequent rollout of a COVID-19 vaccine, questions were raised as to the transparency of these agreements, with a number of lawmakers pointing out that these have not been made publicly available as of yet.

Related Articles